Published on
March 9, 2026
- 17:08 GMT
SHINKEI THERAPEUTICS GETS FDA CLEARANCE FOR MR-101 TRIAL & COMPLETES PHASE 2 FOR MR-301 IN TRAUMATIC BRAIN INJURY
SHINKEI THERAPEUTICS RECEIVES FDA CLEARANCE TO PROCEED WITH PHASE 1 CLINICAL TRIAL FOR MR-101 AND COMPLETES PHASE 2 CLINICAL TRIAL FOR MR-301 IN SEVERE TBI PRINCETON, NJ, UNITED STATES, March 9, 2026 /EINPresswire.com/ -- SHINKEI Therapeutics, Inc., a …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
